Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.37 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 5/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10390219 | 1.00 | HTR1A (0.37) | HTR1APDPK1MTNR1AMTNR1BDRD2 | |
| SCHEMBL10390238 | 0.86 | HTR1A (0.38) | HTR1APDPK1MTNR1AMTNR1BDRD2 | |
| SCHEMBL3433317 | 0.82 | DRD2 (0.36) | HTR1ADRD2 | |
| SCHEMBL7977539 | 0.79 | GRIN2B (0.43) | HTR1A | |
| SCHEMBL1752693 | 0.77 | HTR1A (0.41) | HTR1A | |
| SCHEMBL2183528 | 0.75 | PDPK1 (0.37) | PDPK1MTNR1AMTNR1BDRD2PLAU | |
| SCHEMBL1383876 | 0.71 | ANPEP (0.39) | PDPK1MTNR1AMTNR1BPLAU | |
| SCHEMBL3653495 | 0.71 | PLAU (0.41) | PDPK1PLAU | |
| SCHEMBL5714371 | 0.70 | PRCP (0.36) | HTR1APDPK1MTNR1AMTNR1BDRD2 | |
| SCHEMBL1634692 | 0.68 | CYP11B2 (0.41) | MTNR1AMTNR1BPLAUMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291728-A1 | EPOXY COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE EPOXY RESIN COMPOSITION | DAICEL CORPORATION (JP) | 2015-10-15 | — | — | US | disclosed |
| EP-2921513-A1 | EPOXY COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE EPOXY RESIN COMPOSITION | Daicel Corporation (JP) | 2015-09-23 | — | — | EP | disclosed |
| US-5502207-A | ALKENYL-SUBSTITUTED BISNADIMIDE | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 1996-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291728-A1 | EPOXY COMPOUND, PRODUCTION METHOD THEREFOR, AND CURABLE EPOXY RESIN COMPOSITION | CBR1, SEM1, EEF1A1 | HTR1A 1196/4885PDPK1 4402/4885MTNR1A 2557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.